Glivec in Prostate Cancer Patients With Rising PSA Following Radical Prostectomy

Summary

To investigate the ability of 600 mg of Glivec®, given once daily by mouth to patients with rising PSA following radical prostatectomy, to produce a sustained biochemical response during the first 6 months of treatment.

Timeline

Start

2003-06

Primary completion

2010-07

Completion

—

Drugs

Indications